Holdaway I M, Ibbertson H K, Croxson M S, Harvey V, Boulton J, List A, Rutland M, Knox B S
Department of Endocrinology, Auckland Hospital, New Zealand.
Prostate. 1988;12(2):119-27. doi: 10.1002/pros.2990120203.
A long-acting LRH agonist (ICI 118630, Zoladex) was given by monthly subcutaneous injection to 25 patients with previously untreated symptomatic advanced prostatic carcinoma. The medication was well tolerated with the only side effect being hot flushes in 15 patients. Subjective improvement occurred in 22 patients, and disease remission or stabilization judged by objective criteria was seen in 21 and 18 patients from the total group at 3 and 6 months of treatment, respectively. Twelve of 18 patients followed for 1 year were still in objective remission/stabilization. Prostate volume measured by ultrasound decreased by a mean value of 75% and urine flow increased significantly. There were significant falls in serum testosterone and gonadotrophin levels and significant although lesser reductions in serum androstenedione and dehydroepiandrosterone. These changes were accompanied by significant reductions in serum acid and alkaline phosphatase and a rise in serum osteocalcin. Four patients (16%) experienced an initial tumor flare. Although only a small number of patients were studied, Zoladex appeared to be a well-tolerated agent for treatment of prostatic carcinoma, with an initial clinical response similar to that seen with standard endocrine therapy.
对25例既往未经治疗的有症状的晚期前列腺癌患者每月皮下注射长效促黄体生成素释放激素激动剂（ICI 118630，戈舍瑞林）。该药物耐受性良好，仅15例患者出现潮热这一副作用。22例患者有主观改善，在治疗3个月和6个月时，分别有21例和18例患者经客观标准判断疾病缓解或稳定。18例随访1年的患者中有12例仍处于客观缓解/稳定状态。超声测量前列腺体积平均下降75%，尿流显著增加。血清睾酮和促性腺激素水平显著下降，血清雄烯二酮和脱氢表雄酮也有显著但较小幅度的下降。这些变化伴随着血清酸性和碱性磷酸酶显著降低以及血清骨钙素升高。4例患者（16%）出现初始肿瘤 flare。尽管仅研究了少数患者，但戈舍瑞林似乎是一种耐受性良好的前列腺癌治疗药物，其初始临床反应与标准内分泌治疗相似。
